## Drug Monograph

| | |
|---|---|
| Drug/Drug Class: | **Lucentis® (ranibizumab) solution for injection/ Monoclonal Antibody Fragment** |
| Prepared for: | MO HealthNet |
| Prepared by: | Conduent-Heritage |

☒ **New Criteria** ☐ **Revision of Existing Criteria**

## Executive Summary

| | |
|---|---|
| **Purpose:** | The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use. |
| **Dosage Forms:** | Lucentis® is now available in a single use, prefilled syringe designed to deliver 0.05 ml of 10 mg/ml ranibizumab solution. |
| **Manufacturer:** | Genentech, Inc., South San Francisco, CA 94080 |
| **Indications:** | Lucentis® is indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Myopic Choroidal Neovascularization (mCNV). |
| **Costs:** | $39,390 per syringe of Lucentis®. Maximum Allowable Cost |
| **Summary of Findings:** | MO HealthNet Division recommends Open Access status for this product. |
| **Status Recommendation:** | ☐ Prior Authorization (PA) Required ☒ Open Access<br>☐ Fiscal Edit ☐ PDL |
| **Type of PA Criteria:** | ☐ Increased Risk of ADE ☐ Under Solicitation<br>☐ Appropriate Indications ☒ No PA Required |

Prepared By: Luke Boehmer Pharm.D.
Date: May 24, 2017

© 2017 Conduent Business Services, LLC All Rights Reserved.